Results 51 to 60 of about 3,892 (211)

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Psychedelics and immunomodulation: Novel approaches and therapeutic opportunities

Frontiers in Immunology, 2015
Classical psychedelics are psychoactive substances, which, besides their psychopharmacological activity, have also been shown to exert significant modulatory effects on immune responses by altering signaling pathways involved in inflammation, cellular ...
Attila eSzabo
doaj   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

N,N‐dimethyltryptamine affects electroencephalography response in a concentration‐dependent manner—A pharmacokinetic/pharmacodynamic analysis

CPT: Pharmacometrics & Systems Pharmacology, 2023
N,N‐dimethyltryptamine (DMT) is a psychedelic substance and is being used as a research tool in investigations of the neurobiology behind the human consciousness using different brain imaging techniques.
Emma Eckernäs, Christopher Timmermann, Robin Carhart‐Harris, Daniel Röshammar, Michael Ashton   +4 more
doaj   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction, EarlyView.
Abstract Background and aims This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT; BPL‐003) administered alongside psychological
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, James J. Rucker, Anthony Cleare, John Marsden   +6 more
wiley   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects

PCN Reports, 2023
Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis.
Simon G. D. Ruffell, Max Crosland‐Wood, Rob Palmer, Nige Netzband, WaiFung Tsang, Brandon Weiss, Sam Gandy, Tessa Cowley‐Court, Andreas Halman, Diana McHerron, Angelina Jong, Tom Kennedy, Eleanor White, Daniel Perkins, Devin B. Terhune, Jerome Sarris   +15 more
doaj   +1 more source

Effects of hallucinogenic drugs on the human heart

Frontiers in Pharmacology
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT2A-serotonin receptors in the brain.
Joachim Neumann, Stefan Dhein, Uwe Kirchhefer, Britt Hofmann, Ulrich Gergs   +4 more
doaj   +1 more source

Trends in new psychoactive substance poisonings in the Netherlands: A 14‐year retrospective analysis (2012–2025)

Addiction, Volume 121, Issue 10, Page 2822-2832, October 2026.
Abstract Background and aims Data on the presence of new psychoactive substances (NPS) mainly originate from drug‐checking, law enforcement and wastewater analysis sources, while data on NPS poisonings are scarce. In Europe, the documented incidence rate of NPS poisonings is highest in the Netherlands.
Johanna J. Nugteren‐van Lonkhuyzen, Irma S. van den Hengel‐Koot, Claudine C. Hunault, Dylan W. de Lange, Antoinette J. H. P. van Riel, Laura Hondebrink   +5 more
wiley   +1 more source